Cervical Cancer

Expanding the current HPV vaccination program in the United States to include men and women up to age 45 years may only produce small additional benefits and is not nearly as cost-effective as it is among younger age groups, according to a study published in the Annals of Internal Medicine.

Cancer incidence rates represent one key measure of progress in the fight against cancer, but they are not the only consideration. According to a special report published in The New England Journal of Medicine, concordance between incidence and mortality rates provides a more complete picture of cancer burden.

Infectious Disease News Chief Medical Editor Paul A. Volberding, MD, spoke with Healio about which types of cancer patients with HIV are more likely to develop, how HIV treatments have changed that risk, how cancer affects HIV treatment and how to increase cancer treatment among these patients.

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.

Nivolumab showed promising efficacy among women with recurrent or metastatic cervical, vaginal or vulvar cancers, according to results from the single-arm phase 1/phase 2 CheckMate 358 trial published in Journal of Clinical Oncology.

Women with cervical cancer who experienced psychiatric disorders and stress around the time of diagnosis demonstrated higher rates of cancer-specific mortality than women without such distress at diagnosis, according to study results published in Cancer Research.